0001104659-26-027163
SEC filingVuzix Corporation reported a net loss of $32.3 million for FY 2025, an improvement from a $73.5 million loss in FY 2024. Total sales increased 9% year-over-year to $6.3 million, driven by a 4% increase in product sales to $4.7 million and a 27% increase in engineering services revenue to $1.6 million. The company's gross loss narrowed significantly to $1.1 million from $5.6 million in the prior year, primarily due to a substantial reduction in inventory obsolescence charges. Operating expenses totaled $31.4 million, including significant impairment charges on intangible assets and equity investments. The company ended the year with $21.2 million in cash and cash equivalents, having raised $24.4 million from financing activities including a $10 million preferred stock sale to Quanta Computer and $14.3 million from its ATM program.
Vuzix Corporation reported a net loss of $32,273,128 for FY 2025, representing a significant improvement from the $73,538,157 loss in FY 2024. Total sales increased 9% year-over-year to $6,280,611, driven by growth in both product sales ($4,676,632, up 4%) and engineering services ($1,603,979, up 27%). The company's gross loss narrowed substantially to $1,062,394 from $5,599,670 in the prior year, primarily due to a reduction in inventory obsolescence charges from $4,167,917 in FY 2024 to $503,400 in FY 2025. Operating expenses totaled $31,447,500, including $30,301,355 in impairment charges on intangible assets and equity investments. The company ended the period with $21,150,213 in cash and cash equivalents, having raised $24,371,250 from financing activities.
Revenue growth was driven by increased sales of Vuzix-branded smart glasses, particularly the M400 product line, which saw higher unit sales compared to the prior year. Engineering services revenue increased 27% to $1,603,979, reflecting continued work with ODM/OEM customers. The company's product portfolio includes multiple smart glasses models (M400/M4000, Blade 2, Shield, Ultralite Z100, LX1) targeting enterprise, medical, defense, and select consumer applications. Sales are conducted through a mix of direct sales, value-added resellers, distributors, and ODM/OEM partnerships globally, with operations in the U.S., Japan, and Europe.
The gross margin improved significantly to -17% from -97% in the prior year, primarily due to reduced inventory obsolescence charges. Cost of sales totaled $7,343,005, including $5,490,103 for products sold and $671,571 for engineering services. Operating expenses included $12,625,556 for research and development (up 31% year-over-year), $5,478,596 for selling and marketing (down 33%), and $11,631,818 for general and administrative (down 32%). The company recorded a $30,301,355 impairment charge on intangible assets and equity investments related to the Atomistic technology license termination. Research and development expenses increased due to external development costs for the new LX1 smart glasses and waveguide products.
Net cash used in operating activities was $18,789,272, an improvement from $23,739,372 in the prior year. Investing activities used $2,618,270 for manufacturing equipment, patents, and investments. Financing activities provided $24,371,250, including $10,000,000 from the sale of Series B Preferred Stock to Quanta Computer and $14,286,816 from the ATM program. The balance sheet shows total assets of $40,100,000, with current assets of $27,195,727 and current liabilities of $4,888,202, resulting in positive working capital of $22,307,525. Total liabilities were $5,390,000, and stockholders' equity was $24,710,000. The company had an accumulated deficit of $399,858,410 as of December 31, 2025.
The company faces significant challenges including ongoing net losses, accumulated deficit of $399.9 million, and competitive pressures in the smart glasses market. Management plans to reduce operating expenses, delay non-essential capital expenditures, and pursue licensing opportunities with OEMs. The company expects margin improvement from volume manufacturing of waveguides for OEM customers. Vuzix maintains a strong intellectual property portfolio with 306 issued patents and 202 pending applications globally. Key risks include dependence on third-party technology, supply chain vulnerabilities, cybersecurity threats, and the need to raise additional capital to fund operations. The company has an effective shelf registration for up to $50 million in common stock sales through its ATM program.